Page 9 - AUQ2022Abstracts

Session I

NHA use by chemotherapy status (chemotherapy-naive vs. post-chemo- prescriptions by urologists increased from 22% in 2012 to 42% in 2016.
therapy) and prescribing specialty (medical oncology vs. urology vs. Adjusted analyses show that urologists were more likely to prescribe ENZ
others). In the secondary analyses, we described the trends in the years over ABI, relative to medical oncologists.
when both ABI and ENZ were available, from 2014–2016 (ENZ-era), Conclusions: Over time, there was an increasing proportion 1) patients
stratified by NHA type, chemotherapy status, and prescribing specialty. who initiated NHAs without prior chemotherapy treatment; 2) NHA pre-
Results: The cohort comprises 2183 patients, with 1562 (72%) in the scribing by urologists, and 3) ENZ users. Further research examining
chemotherapy-naive group and 621 (28%) in the post-chemotherapy exactly how the introduction of NHAs has impacted disease management
group. While the majority of patients were post-chemotherapy NHA and referral patterns in advanced PCa may be of interest to clinicians
users in 2012, this proportion decreased over time and accounted for and policymakers.
only 13% of NHA users by the end of 2016. Medical oncologists were
the most frequent prescribers of NHAs (upwards of 60%) throughout
2012 but fell to 45% by the end of 2016. Conversely, the proportion of

CUAJ • Décembre 2022 • volume 16, numéro 12S3 S209